ArticleTherapeutics and clinical risk management2025
Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events.
Eduard Sidelnikov et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.